Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

Boehringer Ingelheim GmbH

Deciphera Pharmaceuticals, LLC

Pfizer Inc.

AB Science SA

Boehringer Ingelheim GmbH

Deciphera Pharmaceuticals, LLC

Pfizer Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tyrosine Protein ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Overview 6

Therapeutics Development 7

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Products under Development by Stage of Development 7

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Products under Development by Therapy Area 8

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Products under Development by Indication 9

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Products under Development by Companies 13

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Companies Involved in Therapeutics Development 23

AB Science SA 23

Boehringer Ingelheim GmbH 25

Deciphera Pharmaceuticals, LLC 26

Pfizer Inc. 27

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Drug Profiles 28

bosutinib - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

masitinib - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

nintedanib - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

rebastinib tosylate - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

tolimidone - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Dormant Projects 60

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Discontinued Products 62

Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Featured News & Press Releases 63

Jul 11, 2016: AB Science Announces The Publication In The Journal Of Neuroinflammation Of Preclinical Data Showing Neuroprotective Effect Of Masitinib In Amyotrophic Lateral Sclerosis 63

Jul 11, 2016: FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis 64

Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund 64

Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) 65

Jun 30, 2016: INMARK now enrolling: first study to evaluate the effect of OFEV (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients 66

Jun 27, 2016: New analysis of INPULSIS trials demonstrates efficacy of OFEV (nintedanib) across a range of IPF patients using broader diagnostic criteria 67

Jun 13, 2016: Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study 68

Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization 69

May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 70

May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 71

May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma 73

May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 74

Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) 74

Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, 78

Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis 79

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 81

Disclaimer 82

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of ...

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 (Contd..1) 15

Products under Development by Companies, H2 2016 (Contd..2) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by AB Science SA, H2 2016 23

Pipeline by Boehringer Ingelheim GmbH, H2 2016 25

Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 26

Pipeline by Pfizer Inc., H2 2016 27

Dormant Projects, H2 2016 60

Dormant Projects (Contd..1), H2 2016 61

Discontinued Products, H2 2016 62

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of ...

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports